Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 1
2013 2
2016 2
2017 1
2018 4
2019 4
2020 6
2021 11
2022 14
2023 8
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Genomics to select treatment for patients with metastatic breast cancer.
Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, Sablin MP, Campone M, Bonnefoi H, Lefeuvre-Plesse C, Jacot W, Coussy F, Ferrero JM, Emile G, Mouret-Reynier MA, Thery JC, Isambert N, Mege A, Barthelemy P, You B, Hajjaji N, Lacroix L, Rouleau E, Tran-Dien A, Boyault S, Attignon V, Gestraud P, Servant N, Le Tourneau C, Cherif LL, Soubeyran I, Montemurro F, Morel A, Lusque A, Jimenez M, Jacquet A, Gonçalves A, Bachelot T, Bieche I. Andre F, et al. Among authors: coussy f. Nature. 2022 Oct;610(7931):343-348. doi: 10.1038/s41586-022-05068-3. Epub 2022 Sep 7. Nature. 2022. PMID: 36071165 Clinical Trial.
Circulating tumor cells: clinical validity and utility.
Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga JY, Bidard FC. Cabel L, et al. Among authors: coussy f. Int J Clin Oncol. 2017 Jun;22(3):421-430. doi: 10.1007/s10147-017-1105-2. Epub 2017 Feb 25. Int J Clin Oncol. 2017. PMID: 28238187 Review.
Expanding biomarkers for PARP inhibitors.
Coussy F, Bidard FC. Coussy F, et al. Nat Cancer. 2022 Oct;3(10):1141-1143. doi: 10.1038/s43018-022-00440-8. Nat Cancer. 2022. PMID: 36253485 No abstract available.
Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.
Ter Brugge P, Moser SC, Bièche I, Kristel P, Ibadioune S, Eeckhoutte A, de Bruijn R, van der Burg E, Lutz C, Annunziato S, de Ruiter J, Masliah Planchon J, Vacher S, Courtois L, El-Botty R, Dahmani A, Montaudon E, Morisset L, Sourd L, Huguet L, Derrien H, Nemati F, Chateau-Joubert S, Larcher T, Salomon A, Decaudin D, Reyal F, Coussy F, Popova T, Wesseling J, Stern MH, Jonkers J, Marangoni E. Ter Brugge P, et al. Among authors: coussy f. Nat Commun. 2023 Apr 7;14(1):1958. doi: 10.1038/s41467-023-37537-2. Nat Commun. 2023. PMID: 37029129 Free PMC article.
Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns.
Gougis P, Grandal B, Jochum F, Bihan K, Coussy F, Barraud S, Asselain B, Dumas E, Sebbag C, Hotton J, Spaggiari E, Pierga JY, Savarino R, Laas E, Spano JP, Reyal F, Hamy AS. Gougis P, et al. Among authors: coussy f. JAMA Netw Open. 2023 Oct 2;6(10):e2339934. doi: 10.1001/jamanetworkopen.2023.39934. JAMA Netw Open. 2023. PMID: 37883083 Free PMC article.
HORMAD1 overexpression predicts response to anthracycline-cyclophosphamide and survival in triple-negative breast cancers.
El-Botty R, Vacher S, Mainguené J, Briaux A, Ibadioune S, Dahmani A, Montaudon E, Nemati F, Huguet L, Sourd L, Morriset L, Château-Joubert S, Dubois T, Maire V, Lidereau R, Rapinat A, Gentien D, Coussy F, Bièche I, Marangoni E. El-Botty R, et al. Among authors: coussy f. Mol Oncol. 2023 Oct;17(10):2017-2028. doi: 10.1002/1878-0261.13412. Epub 2023 Mar 23. Mol Oncol. 2023. PMID: 36852691 Free PMC article.
[Vitamin D and cancers].
Espié M, Wassermann J, de Kermadec E, Lalloum M, Coussy F. Espié M, et al. Among authors: coussy f. Presse Med. 2013 Oct;42(10):1405-11. doi: 10.1016/j.lpm.2013.07.013. Epub 2013 Sep 17. Presse Med. 2013. PMID: 24051164 Review. French.
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast.
Agostinetto E, Nader-Marta G, Paesmans M, Ameye L, Veys I, Buisseret L, Neven P, Taylor D, Fontaine C, Duhoux FP, Canon JL, Denys H, Coussy F, Chakiba C, Ribeiro JM, Piccart M, Desmedt C, Ignatiadis M, Aftimos P. Agostinetto E, et al. Among authors: coussy f. Future Oncol. 2022 Jul;18(22):2383-2392. doi: 10.2217/fon-2022-0358. Epub 2022 Jun 13. Future Oncol. 2022. PMID: 35695563 Review.
51 results